click
Contact

NAMs: MODEL-INFORMED DRUG DEVELOPMENT BASED PREDICTION BY INTEGRATING AI-ADMET WITH PBPK

NAMs: MODEL-INFORMED DRUG DEVELOPMENT BASED PREDICTION BY INTEGRATING AI-ADMET WITH PBPK

Facebook
LinkedIn

Fill out the form below to download this content.

NAMs: MODEL-INFORMED DRUG DEVELOPMENT BASED PREDICTION BY INTEGRATING AI-ADMET WITH PBPK

NAMs: MODEL-INFORMED DRUG DEVELOPMENT BASED PREDICTION BY INTEGRATING AI-ADMET WITH PBPK

Name(Required)
By clicking submit you consent to receive email communications about products and services of Medicilon and are in accordance with our Privacy Policy. You may opt out at any time.
Contact

Search Medicilon

NAMs: MODEL-INFORMED DRUG DEVELOPMENT BASED PREDICTION BY INTEGRATING AI-ADMET WITH PBPK

Read more
Medicilon Events

50th Korean Society of Nonclinical Studies (KSNS)

Read more
Preclinical CRO

Medicilon Congratulates : MindRank AI-Developed Oral GLP-1 MDR-001 Secures Up to RMB 1.75 Billion Exclusive Commercialization Deal with Sunshine Mandi

Read more

Contact Medicilon

Name(Required)
Address(Required)